KEYMED BIO-B(02162)
38.200-1.000-2.55%
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
- KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic RhinitisKeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis
THOMSON REUTERS · 02-08
- KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic RhinitisKeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis
THOMSON REUTERS · 02-08
- Keymed Biosciences Get China Nod for Supplementary NDA of Rhinitis DrugKeymed Biosciences Get China Nod for Supplementary NDA of Rhinitis Drug
MT Newswires Live · 02-07
- KeyMed Biosciences - Nmpa Approved Snda of Stapokibart for Treatment of Seasonal Allergic RhinitisKeyMed Biosciences - Nmpa Approved Snda of Stapokibart for Treatment of Seasonal Allergic Rhinitis
THOMSON REUTERS · 02-07
- Keymed-Innocare JV Signs Commercial License Deal for Anti-Tumor DrugKeymed-Innocare JV Signs Commercial License Deal for Anti-Tumor Drug
MT Newswires Live · 01-21
- InnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor DrugInnoCare Pharma Unit Outsources Manufacturing, Commercialization License for Tumor Drug
MT Newswires Live · 01-21
- InnoCare and KeyMed Jointly Announce the License Agreement With Prolium for Cd20xcd3 Bispecific Antibody Icp-B02InnoCare and KeyMed Jointly Announce the License Agreement With Prolium for Cd20xcd3 Bispecific Antibody Icp-B02
THOMSON REUTERS · 01-20
- BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355
Reuters · 01-20
- KeyMed Biosciences Inc - Chengdu KeyMed and Beijing InnoCare Will Receive $17.5 Mln, and Additional Payments up to US$502.5 MlnKeyMed Biosciences Inc - Chengdu KeyMed and Beijing InnoCare Will Receive $17.5 Mln, and Additional Payments up to US$502.5 Mln
THOMSON REUTERS · 01-20
- KeyMed Biosciences - License Agreement With Prolium for Development and Commercialization of Cm355KeyMed Biosciences - License Agreement With Prolium for Development and Commercialization of Cm355
THOMSON REUTERS · 01-20
- Keymed Biosciences' Unit Signs License Deal for Drug's CommercializationKeymed Biosciences' Unit Signs License Deal for Drug's Commercialization
MT Newswires Live · 01-10
- Press Release: Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical NeedsPress Release: Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs
Dow Jones · 01-10
- KeyMed Biosciences Inc - Group to Receive Upfront and Near-Term Payment of US$30 Mln & Stake of Timberlyne TherapeuticsKeyMed Biosciences Inc - Group to Receive Upfront and Near-Term Payment of US$30 Mln & Stake of Timberlyne Therapeutics
THOMSON REUTERS · 01-10
- KeyMed Biosciences Inc-License Deal Grants Timberlyne Therapeutics Exclusive Right to Develop, Others Cm313 Globally Excl. Mainland China, OthersKeyMed Biosciences Inc-License Deal Grants Timberlyne Therapeutics Exclusive Right to Develop, Others Cm313 Globally Excl. Mainland China, Others
THOMSON REUTERS · 01-10
- KeyMed Biosciences Inc - Unit and Timberlyne Therapeutics, Inc. Entered Exclusive Out-License AgreementKeyMed Biosciences Inc - Unit and Timberlyne Therapeutics, Inc. Entered Exclusive Out-License Agreement
THOMSON REUTERS · 01-10
- KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal PolyposisKeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis
THOMSON REUTERS · 2024-12-23
- KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal PolyposisKeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis
THOMSON REUTERS · 2024-12-23
- Keymed Biosciences' Supplemental NDA for Rhinosinusitis Drug Gets China NodKeymed Biosciences' Supplemental NDA for Rhinosinusitis Drug Gets China Nod
MT Newswires Live · 2024-12-23
- KeyMed Biosciences Inc - Nmpa China Approved Snda of Stapokibart- for Treatment of Chronic Rhinosinusitis- With Nasal PolyposisKeyMed Biosciences Inc - Nmpa China Approved Snda of Stapokibart- for Treatment of Chronic Rhinosinusitis- With Nasal Polyposis
THOMSON REUTERS · 2024-12-23
- Institutions along with individual investors who hold considerable shares inKeymed Biosciences Inc. (HKG:2162) come under pressure; lose 7.1% of holdings value
Simply Wall St. · 2024-12-14
Institutions along with individual investors who hold considerable shares inKeymed Biosciences Inc. (HKG:2162) come under pressure; lose 7.1% of holdings value
High
39.200
Open
39.200
Volume%
2.22
Low
36.350
Close
39.200
T/O Rate
1.44%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial